文献速递妇科

卵巢癌的预防与筛查

Ovarian Cancer Prevention and Screening.
PubMed 文献 · Obstet Gynecol · 2018-01-01

本文综述了卵巢癌筛查与预防的近期进展:结合遗传与流行病学因素的个体风险预测工具有望用于定制预防和筛查策略;输卵管起源证据支持在一般人群的输卵管结扎和子宫切除术中行机会性双侧输卵管切除术;英国协作卵巢癌筛查试验报告年度多模式筛查(纵向CA 125风险算法)出现分期偏移但未显著降低死亡率;高危人群风险降低性输卵管卵巢切除术仍是标准治疗,同时正在评估早期双侧输卵管切除术与延迟卵巢切除术。

要点

  • 一般人群中,英国协作卵巢癌筛查试验报告年度多模式筛查(纵向CA 125风险算法)出现分期偏移,但两种筛查策略均无明确死亡率降低。
  • 输卵管起源证据支持在一般人群的输卵管结扎和子宫切除术中行机会性双侧输卵管切除术,临床试验正在评估对内分泌功能的长期影响。
  • 高危女性中风险降低性输卵管卵巢切除术仍是标准治疗,目前关注非癌症结局(尤其是年轻女性性功能障碍)的管理。

核心结论

  • 一般人群尚无证据支持筛查;高危人群筛查建议各国不同,高危女性风险降低性输卵管卵巢切除术仍是标准治疗。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 英国协作卵巢癌筛查试验报告年度多模式筛查(纵向CA 125风险算法)出现分期偏移,但年度经阴道超声筛查未出现分期偏移;两种筛查策略与不筛查相比均无明确死亡率降低,进一步随访至2018年12月正在进行中。
  • 英国和美国高危筛查试验中,每3至4个月多模式筛查也报告了分期偏移和更高的满意肿瘤细胞减灭率。
  • 筛查试验的关键发现是纵向算法在CA 125性能上优于单次截断值。
  • 模型提示BRCA突变携带者应考虑使用口服避孕药进行化学预防。

关键数值与推荐

  • 一般人群:英国协作卵巢癌筛查试验报告年度多模式筛查(纵向CA 125风险算法)出现分期偏移,但两种筛查策略均无明确死亡率降低。
  • 高危人群:风险降低性输卵管卵巢切除术仍是标准治疗;正在评估早期双侧输卵管切除术与延迟卵巢切除术。
  • 模型提示BRCA突变携带者可考虑口服避孕药进行化学预防。

临床怎么用

  • 一般人群可在输卵管结扎和子宫切除术时行机会性双侧输卵管切除术,临床试验正在评估对内分泌功能的长期影响。
  • 高危女性风险降低性输卵管卵巢切除术仍是标准治疗,目前关注非癌症结局(尤其是年轻女性性功能障碍)的管理。
  • 作者指出尚无证据支持一般人群筛查,高危人群筛查建议各国不同。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There has been much progress in ovarian cancer screening and prevention in recent years. Improved tools that combine genetic and epidemiologic factors to predict an individual's ovarian cancer risk are set to become available for tailoring preventive and screening approaches. The increasing evidence on tubal origins of a proportion of ovarian cancer has paved the way to use of opportunistic bilateral salpingectomy at tubal ligation and hysterectomy in the general population. Clinical trials are in progress to estimate the long-term effects on endocrine function. In women at high risk, risk reducing salpingo-oophorectomy remains the standard of care with the current focus on management of resulting noncancer outcomes, especially sexual dysfunction in younger women. This has led to evaluation of early bilateral salpingectomy and delayed oophorectomy in this population. Meanwhile, modeling suggests that BRCA mutation carriers should consider using the oral contraceptive pill for chemoprevention. In the general population, the largest ovarian cancer screening trial to date, the UK Collaborative Trial of Ovarian Cancer Screening reported a stage shift with annual multimodal screening using the longitudinal CA 125 Risk of Ovarian Cancer Algorithm but not with annual transvaginal ultrasound screening. There was no definitive mortality reduction with either screening strategy compared with no screening. Further follow-up until December 2018 in now underway. Stage shift and higher rates of optimal cytoreduction were also reported during 3- to 4-monthly multimodal screening in the United Kingdom and U.S. high-risk screening trials. Although all agree that there is not yet evidence to support general population screening, recommendations for high-risk screening vary between countries. A key finding from the screening trials has been the better performance of longitudinal algorithms compared with a single cutoff for CA 125. A major focus of ovarian cancer biomarker discovery work has been tumor DNA markers in both plasma and novel specimens such as cervical cytology samples.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Menon U, Karpinskyj C, Gentry-Maharaj A, et al. Ovarian Cancer Prevention and Screening. Obstet Gynecol. 2018. PMID: 29630008. doi:10.1097/AOG.0000000000002580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。